Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Neurotherapeutics ; 18(2): 1175-1187, 2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33594533

RESUMO

Fragile X syndrome (FXS) is a genetic neurodevelopmental syndrome characterized by increased anxiety, repetitive behaviors, social communication deficits, delayed language development, and abnormal sensory processing. Recently, we have identified electroencephalographic (EEG) biomarkers that are conserved between the mouse model of FXS (Fmr1 KO mice) and humans with FXS. In this study, we test a specific candidate mechanism for engagement of multielectrode array (MEA) EEG biomarkers in the FXS mouse model. We administered TAK-063, a potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor, to Fmr1 KO mice, and examined its effects on MEA EEG biomarkers. We demonstrate significant dose-related amelioration of inter-trial phase coherence (ITPC) to temporally modulated auditory stimuli by TAK-063 in Fmr1 KO mice. Our data suggest that TAK-063 improves cortical auditory stimulus processing in Fmr1 KO mice, without significantly depressing baseline EEG power or causing any noticeable sedation or behavioral side effects. Thus, the PDE10A inhibitor TAK-063 has salutary effects on normalizing EEG biomarkers in a mouse model of FXS and should be pursued in further translational treatment development.


Assuntos
Estimulação Acústica/efeitos adversos , Eletroencefalografia/efeitos dos fármacos , Síndrome do Cromossomo X Frágil/tratamento farmacológico , Inibidores de Fosfodiesterase/uso terapêutico , Diester Fosfórico Hidrolases , Pirazóis/uso terapêutico , Piridazinas/uso terapêutico , Animais , Eletroencefalografia/métodos , Proteína do X Frágil da Deficiência Intelectual/genética , Síndrome do Cromossomo X Frágil/genética , Síndrome do Cromossomo X Frágil/fisiopatologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Camundongos Transgênicos , Inibidores de Fosfodiesterase/farmacologia , Pirazóis/farmacologia , Piridazinas/farmacologia
2.
Ann Allergy Asthma Immunol ; 105(3): 191-9; quiz 200-2, 217, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20800785

RESUMO

OBJECTIVE: To review the current literature on vitamin D and asthma, discussing the possible roles of vitamin D on asthma pathogenesis and the potential consequences of vitamin D deficiency. DATA SOURCES: PubMed database was searched from 1950 to 2009. Keywords used included asthma, vitamin D, inflammation, airway smooth muscle and cytokines. STUDY SELECTION: Articles were selected based on relevance to the subject. RESULTS: Vitamin D deficiency has been associated with epidemiologic patterns observed in the asthma epidemic. Vitamin D deficiency is more common with obesity, African American ethnicity, and westernization of countries with higher-risk populations for asthma. Evidence suggests that vitamin D deficiency is associated with increased airway hyperresponsiveness, lower pulmonary functions, worse asthma control, and possibly steroid resistance. Lung epithelial cells express high baseline levels of 1alpha-hydroxylase. This allows the conversion of inactive calcidiol to active calcitriol locally within the lung. Calcitriol has been shown to inhibit the synthesis and release of certain cytokines, such as RANTES, platelet-derived growth factor, and matrix metalloproteinases, from bronchial smooth muscle cells, thereby leading to decreased lung inflammation and smooth muscle cell proliferation. Vitamin D also increases synthesis of interleukin 10 by CD4+CD25+Foxp3+ T-regulatory cells and dendritic cells, while concurrently inhibiting dendritic cell activation by downregulating expression of costimulatory molecules CD40 and CD80/86. Vitamin D is also capable of inducing the expression of several anti-infective molecules, such as cathelicidin. Thus, vitamin D has a number of biologic effects that are likely important in regulating key mechanisms in asthma. CONCLUSIONS: We hypothesize that vitamin D supplementation may lead to improved asthma control by inhibiting the influx of inflammatory cytokines in the lung and increasing the secretion of interleukin 10 by T-regulatory cells and dendritic cells.


Assuntos
Anti-Inflamatórios/imunologia , Asma/imunologia , Mucosa Respiratória/metabolismo , Deficiência de Vitamina D/imunologia , Vitamina D/imunologia , Animais , Anti-Inflamatórios/uso terapêutico , Asma/tratamento farmacológico , Asma/epidemiologia , Calcitriol/metabolismo , Calcitriol/farmacologia , Células Dendríticas/efeitos dos fármacos , Células Dendríticas/imunologia , Suplementos Nutricionais , Humanos , Mediadores da Inflamação/antagonistas & inibidores , Interleucina-10/metabolismo , Mucosa Respiratória/imunologia , Mucosa Respiratória/patologia , Fatores de Risco , Esteroide 17-alfa-Hidroxilase/imunologia , Esteroide 17-alfa-Hidroxilase/metabolismo , Linfócitos T Reguladores/efeitos dos fármacos , Linfócitos T Reguladores/imunologia , Vitamina D/uso terapêutico , Deficiência de Vitamina D/tratamento farmacológico , Deficiência de Vitamina D/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA